Core Insights - Onco360 has been selected as a pharmacy partner by Nuvation Bio Inc. for IBTROZI™ (taletrectinib), a kinase inhibitor for treating adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) [1] - The approval of IBTROZI is based on Phase 2 TRUST-I and TRUST-II studies involving over 300 patients [1][2] - IBTROZI is a next-generation ROS1 inhibitor therapy that is CNS-active and oral, targeting a rare and aggressive form of lung cancer that accounts for approximately 2% of new NSCLC cases in the U.S. [1] Company Overview - Onco360 is the largest independent Oncology Pharmacy in the U.S., founded in 2003 to meet the specialized needs of oncologists, patients, and healthcare facilities [14] - The company is headquartered in Louisville, Kentucky, and is a flagship specialty pharmacy brand of PharMerica Corporation [14] Product Information - IBTROZI is indicated for adult patients with ROS1-positive NSCLC, which has a median diagnosis age of around 50 years and is more common in non-smokers [1] - The drug has shown a significant potential in treating patients with advanced or metastatic ROS1-positive NSCLC, with approximately 3,000 new diagnoses annually in the U.S. [1] Safety and Efficacy - Hepatotoxicity is a notable risk, with 88% of patients experiencing increased AST levels and 85% experiencing increased ALT levels [2][3] - The median time to first onset of AST or ALT elevation is 15 days, with fatal liver events occurring in 0.6% of patients [2] - Interstitial Lung Disease (ILD) or pneumonitis occurred in 2.3% of patients, with a median onset time of 3.8 months [3][4] - The most frequently reported adverse reactions (≥20%) include diarrhea (64%), nausea (47%), and vomiting (43%) [12] Drug Interactions and Administration - IBTROZI should be administered on an empty stomach and should avoid concomitant use with strong and moderate CYP3A inhibitors [6][15] - The drug can cause significant QTc interval prolongation, which may increase the risk of serious cardiac events [5][6] Conclusion - The partnership between Onco360 and Nuvation Bio for IBTROZI represents a significant advancement in the treatment options available for patients with ROS1-positive NSCLC, addressing a critical need in oncology [1][14]

Core Insights - Emory University and Micron Biomedical have initiated the first clinical trial of a novel rotavirus vaccine, CC24, utilizing dissolvable microarray technology, marking a significant advancement in vaccine delivery methods [1][2][3] Company Insights - Micron Biomedical specializes in dissolvable microarray technology for drug and vaccine administration, aiming to enhance access and health outcomes globally through painless, needle-free self-administration [9] - The company has developed a unique needle-free technology that allows for rapid delivery of vaccines, reducing the need for cold chain logistics and producing no medical sharps waste [3][9] - Micron Biomedical collaborates with various organizations, including the CDC and the Gates Foundation, to advance its technology and improve vaccine accessibility [9] Industry Insights - Rotavirus remains a leading cause of childhood diarrheal deaths, particularly in low- and middle-income countries, where existing oral vaccines are less effective [2][4] - The trial aims to address the limitations of current oral rotavirus vaccines and improve vaccine uptake through innovative delivery methods [4][5] - The study will recruit 50 healthy adults aged 18 to 45, with data expected to inform future studies in children [6][7]

Vancouver, British Columbia--(Newsfile Corp. - June 16, 2025) - South Pacific Metals Corp. (TSXV: SPMC) (OTCQB: SPMEF) (FSE: 6J00) ("SPMC" or "South Pacific Metals" or the "Company") announces that Ms. Cathy Fitzgerald will be stepping down as an officer and director of the Company, effective July 11, 2025.Cathy has played a pivotal role in the growth and strategic direction of South Pacific Metals. As President, her leadership and technical expertise have been instrumental in shaping the Company's explora ...

Taiwan Semiconductor Manufacturing TodayTSMTaiwan Semiconductor Manufacturing$211.07 -4.36 (-2.02%) 52-Week Range$133.57▼$226.40Dividend Yield1.12%P/E Ratio29.98Price Target$217.00Add to WatchlistAny investor who has been exposed to the United States technology sector has learned the meaning of volatility over the past few quarters, especially as President Trump's trade tariffs start to significantly impact the sector’s future expectations and forecasts. However, not all are doomed for this space.Get TSM a ...

Dublin, June 16, 2025 (GLOBE NEWSWIRE) -- The "Unilever Group in Snacks (World)" company profile has been added to ResearchAndMarkets.com's offering.Unilever ranks sixth in overall snacks sales globally, but is the clear leader in the ice cream category, accounting for a fifth of retail value sales worldwide. However, 2024 is expected to be the last one in which Unilever's ice cream business was included in the group's overall earnings figures, with a demerger of this division planned by the company by the ...

Group 1 - DoubleDown Interactive (DDI) experienced a significant decline of 23.7% on June 12 following an insider selling shares at $8.50 each, raising questions about its investment potential [1] - Despite the recent drop, there is a belief that DDI remains a viable investment opportunity [1] Group 2 - The investment strategy focuses on GARP (growth at a reasonable price) stocks while also seeking opportunities in other areas [2] - The investment approach does not adhere to a specific time horizon, with positions held as long as the investment thesis remains valid [2] - The analyst has developed market-beating algorithms using Python to identify attractive investment opportunities [2]

Updated Phase 2 data evaluating ZYNLONTA® as a monotherapy demonstrate overall response rate (ORR) of 85% and complete response (CR) rate of 69% CR maintained in 17 of 18 patients who achieved CR, with longest duration of CR of 27 months from start of treatmentZYNLONTA was generally well tolerated and safety was consistent with known profile LAUSANNE, Switzerland, June 16, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjug ...

Group 1 - Cooper-Standard's stock surged 44% on May 2 following the announcement of Q1 2025 results [1] - The reported EPS of $0.09 significantly exceeded the expected EPS of -$1.14, primarily due to a royalty payment [1] Group 2 - The company is focused on identifying firms with high potential for revenue and earnings growth that are not fully reflected in current market prices [1] - The investment strategy emphasizes long-term holdings, with a preference for less cyclical and higher growth sectors [1]

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:Flexsteel Industries, Inc. (FLXS) : This manufacturer of upholstered furniture has seen the Zacks Consensus Estimate for its current year earnings increasing 7.4% over the last 60 days.Rockwell Automation, Inc. (ROK) : This industrial automation and digital transformation solutions company has seen the Zacks Consensus Estimate for its current year earnings increasing 5.7% over the last 60 days.The E.W. Scripps Company (SSP) : This media ...

This photo shows signage at a car dealership for Japanese automaker Honda Motor along a street in ... More central Tokyo on May 13, 2025, ahead of the company's annual results announcement later in the day. (Photo by Richard A. Brooks / AFP) (Photo by RICHARD A. BROOKS/AFP via Getty Images)AFP via Getty ImagesJapan’s second-largest automaker, Honda Motor stock (NYSE: HMC), has predominantly fluctuated sideways this year, yielding approximately 2% since the beginning of January. Honda’s recent outcomes have ...